INDBInternet News Database 2.5 Updated just now · 393 sources Show or hide images Light or dark

Study Sees Satralizumab Benefits for TED Over 48 Weeks

Save Like Comments Compare coverage

Summary

Data from a pair of clinical trials show durable improvements in symptoms with the IL-6 receptor inhibitor, but questions over its cost-effectiveness cloud findings.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Study Sees Satralizumab Benefits for TED Over 48 Weeks

    Data from a pair of clinical trials show durable improvements in symptoms with the IL-6 receptor inhibitor, but questions over its cost-effectiveness cloud findings.

Comments

Comments need JavaScript.